INTRODUCTION
In pivotal phase III studies, the epidermal growth factor receptor (EGFR) -targeting monoclonal antibody, cetuximab, has been shown to improve the efficacy of standard chemotherapy regimens used in the first-line treatment of several common cancers, including metastatic colorectal cancer (mCRC). [1] [2] [3] In particular, the CRYSTAL (Cetuximab Combined with Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer) study met its primary end point in demonstrating that the addition of cetuximab to a combined first-line chemotherapy regimen of irinotecan, infusional fluorouracil, and leucovorin (FOLFIRI) statistically significantly reduced the risk of progression of metastatic colorectal cancer (mCRC) compared with chemotherapy alone (hazard ratio [HR] , 0.85; P ϭ .048). 1 The tumor response was also statistically significantly enhanced in the cetuximab plus FOLFIRI arm (odds ratio, 1.40; P ϭ .004), as was the R0 resection rate of metastases with curative intent (P ϭ .002). Overall survival, given a median time of follow-up of nearly 30 months, did not appear to be statistically significantly different between treatment groups (HR, 0.93; P ϭ .31). 1 Confirming earlier observations from singlearm studies, [4] [5] [6] [7] and consistent with analyses in other randomized studies in mCRC involving cetuximab, 8, 9 the clinical activity of cetuximab in the
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CRYSTAL study was shown in a retrospective analysis to be limited to those patients whose tumors were wild-type at codons 12 and 13 of the KRAS gene, a group comprising 64% of the KRAS evaluable population. The benefit in patients with KRAS wild-type tumors was apparent in relation to a significantly reduced risk of disease progression (HR, 0.68; P ϭ .02) and significantly increased odds of response in favor of the cetuximab plus FOLFIRI arm (odds ratio, 1.91). Overall survival also appeared to be improved in patients with KRAS wild-type tumors (HR, 0.84). No benefit for the addition of cetuximab to FOLFIRI was detected for any efficacy end point in patients whose tumors carried mutations of the KRAS gene (progression-free survival [PFS] : HR, 1.07; P ϭ .75; overall survival: HR, 1.03; best overall response: odds ratio, 0.80). In the subgroup of patients evaluated for tumor KRAS mutation status, a significant interaction between treatment group and KRAS status was demonstrated for response (P ϭ .03) but not (in this limited population) for PFS (P ϭ .07) or overall survival (P ϭ .44).
The KRAS analysis was based on the molecular typing of clinical material from a subgroup of 540 patients (45%) of the intention-to-treat (ITT; previously referred to as primary analysis 1 ) population, (the KRAS population). Although comparison of the baseline characteristics and efficacy data suggested that the KRAS population was comparable to the ITT population, it was felt that a more accurate evaluation of the benefit of adding cetuximab to FOLFIRI as first-line treatment for mCRC would be obtained if tumor KRAS mutation status were to be determined for a higher proportion of patients. This article therefore reports an updated analysis of the CRYSTAL study, with increased follow-up time and an increased number of patients evaluable for tumor KRAS status. The BRAF gene, which encodes a downstream effector of KRAS in the mitogen-activated protein kinase pathway, 10 is also mutated in a subset of mCRCs. [11] [12] [13] [14] The clinical significance of the tumor mutation status of BRAF was considered in the expanded population of patients with KRAS wild-type tumors.
PATIENTS AND METHODS

Study Design and Treatment
Eligibility criteria and design have been described. 1 The study was carried out in accordance with the declaration of Helsinki (October 1996). All patients provided informed consent. This was an open-label, randomized, multicenter, phase III study comparing cetuximab plus FOLFIRI with FOLFIRI alone as first-line treatment for mCRC.
On day 1 of a 14-day treatment cycle, patients received cetuximab (initial dose 400 mg/m 2 infused over 2 hours, and 250 mg/m 2 weekly, over 1 hour, thereafter) followed after 1 hour by FOLFIRI (irinotecan 180 mg/m 2 , day 1, infused over 30 to 90 minutes, followed by leucovorin 200 mg/m 2 L-form, or 400 mg/m 2 racemic, infused over 2 hours, followed by fluorouracil, as a 400 mg/m 2 intravenous bolus then a 2,400-mg/m 2 46-hour continuous infusion) or FOLFIRI alone, until disease progression or the occurrence of unacceptable toxicity.
Radiologic assessment of response was carried out every 8 weeks until disease progression or withdrawal. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria, version 2.0. Follow-up evaluations were performed every 3 months.
The primary end point was PFS, as determined by an independent review committee performing a preplanned, blinded review (based on modified WHO criteria) of radiological assessments. Secondary end points included overall survival, best overall response, and safety. A retrospective subgroup analysis investigated associations between tumor KRAS mutation status and outcome.
KRAS and BRAF Mutation Analysis
DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue and the mutation status of codons 12 and 13 of the KRAS gene assessed using a polymerase chain reaction clamping and melting curve technique, as previously described.
1 BRAF mutation status (V600E) was analyzed using a similar approach (LightMix BRAF V600E Kit; TIB MOLBIOL, Germany). The number of evaluable samples was increased from the previous analysis through the extraction of tumor DNA from slide-mounted tissue previously used to assess EGFR expression.
Statistical Methods and Considerations
The primary efficacy analysis of PFS was performed on the ITT population, which comprised all randomly assigned patients who received at least one dose of a study drug. 1 Prespecified analyses were repeated according to KRAS and BRAF tumor mutation status. PFS and overall survival times were analyzed by the Kaplan-Meier method 15 (product limit estimates) and stratified log-rank test. Best overall response rates were compared between treatment groups using Cochran-Mantel-Haenszel tests, stratified according to randomization strata. All reported P values were two sided and given the exploratory nature of the updated analyses, they have not been adjusted for multiple testing. HRs and odds ratios are expressed for cetuximab plus FOLFIRI versus FOLFIRI alone. The interaction of the treatment effect and tumor KRAS status was further explored for PFS and overall survival time using Cox models and for best overall response rate using a logistic regression model by means of deviance tests. The impact of early acne-like rash (any grade) on outcome was explored using a landmark method. 16 Survival time was estimated conditionally according to whether the patient developed acne-like rash within 21 days (landmark period) after the start of study treatment (early acne-like rash). An evaluable population (patients under treatment at day 21) was determined which comprised all ITT patients alive on day 21 and with a treatment duration Ն 21 days; survival times were calculated from the day of first dose of study medication.
Safety analyses were carried out on patients who received at least one dose of any study drug. Adverse events (AEs) were categorized according to the Medical Dictionary for Regulatory Activities (version 10.0) according to preferred terms and predefined special AE categories.
RESULTS
Patients and Samples
The ITT population comprised 1,198 randomly assigned and treated patients, with 599 receiving cetuximab plus FOLFIRI and 599 receiving FOLFIRI alone. The safety population (n ϭ 1,202) included four additional patients who were treated but did not undergo random assignment, with 600 patients receiving cetuximab plus FOLFIRI and 602 FOLFIRI alone (Fig 1) . Subsequent to the initial published analysis which had a cutoff date for overall survival of December 31, 2007, and an associated overall median duration of follow-up of 29.7 months, the extraction of DNA from tumor material recovered from FFPE slides used for immunohistochemical analysis of EGFR expression allowed for the typing of an additional 523 tumors for KRAS mutation status, representing an increase in the ascertainment rate from 45% of ITT population patients in the original analysis to 89% (540 to 1,063) in this analysis (KRAS population). An updated analysis of overall survival was therefore carried out with a new cutoff date of May 31, 2009, giving an overall median duration of follow-up of 46.8 months for patients receiving cetuximab plus FOLFIRI and 46.2 months for those receiving FOLFIRI alone.
Baseline characteristics were essentially well balanced between the treatment groups in the ITT and KRAS populations and between corresponding arms of the subpopulations defined according to KRAS and BRAF mutation status (Table 1; Appendix Table A1 , online only). Exposure to irinotecan and fluorouracil was similar for patients in both treatment groups in the ITT 1 and KRAS populations and within each treatment group, for patients with KRAS wild-type and mutant tumors. In the ITT population, poststudy chemotherapy (or subsequent EGFR-targeted therapy with or without chemotherapy) was received by 65.9% of patients (11.0%) in the cetuximab plus FOLFIRI group and 70.1% (29.7%) of those receiving FOLFIRI alone.
Overall Survival in the ITT Population
As of May 31, 2009, there were 487 deaths (81% of patients) in the cetuximab plus FOLFIRI group and 502 (84% of patients) in the FOLFIRI alone group. The addition of cetuximab to FOLFIRI resulted in a significant improvement in overall survival time, with the stratified HR for death 0.878 (95% CI, 0.774 to 0.995; P ϭ .0419), and median survival times of 19.9 months compared with 18.6 months for FOLFIRI alone (Table 2 , Fig 2A) .
Subgroup Analysis According to Tumor KRAS
Mutation Status
Mutations in KRAS codon 12 or 13 were detected in the tumor tissue of 397 of 1,063 patients (37%). Mutations were found more frequently in the tumor tissue of patients receiving cetuximab plus FOLFIRI (40%) compared with those receiving FOLFIRI alone (34%). The HRs for PFS and overall survival in the ITT and KRAS populations were comparable (Table 2) .
Patients whose tumors were wild-type for KRAS who received cetuximab plus FOLFIRI had a significantly reduced risk of disease progression (median PFS, 9.9 v 8.4 months; HR, 0.696; P ϭ .0012) significantly improved overall survival (median survival, 23.5 v 20.0 months; HR, 0.796; P ϭ .0093) and significantly increased odds of response (best overall response rate 57.3% v 39.7%; odds ratio, 2.069; P Ͻ .001) compared with those who received FOLFIRI alone (Table 2 , Fig 2B; Appendix Fig A1, online only) . Evaluable patients in the cetuximab plus FOLFIRI group with KRAS wildtype tumors who developed early acne-like rash (n ϭ 207) had prolonged median survival times (26.4 v 19.1 months) compared with those not experiencing early acne-like rash (n ϭ 101).
In patients whose tumors carried mutations in KRAS, there was no evidence of a benefit associated with the addition of cetuximab to FOLFIRI in relation to PFS, overall survival, or best overall response. Patients in both treatment groups whose tumors carried mutations in KRAS appeared to have worse overall survival than those whose tumors were wild-type (Table 2 , Fig 2B) . Cox (PFS and overall survival) and logistic regression (best overall response) models were used to explore the relationship in the expanded KRAS population between the magnitude of treatment effect and tumor KRAS mutation status. Significant interactions in the updated data set were noted for PFS (P ϭ .0028), overall survival (P ϭ .0463), and best overall response (P ϭ .0005).
The rate of surgery for metastasis and the rate of R0 resection were both higher in patients with KRAS wild-type tumors who received cetuximab plus FOLFIRI compared with FOLFIRI alone (7.9% v 4.6%; odds ratio, 1.823; 95% CI, 0.957 to 3.472; P ϭ .0633 and 5.1% v 2.0%; odds ratio, 2.650; 95% CI, 1.083 to 6.490; P ϭ .0265, respectively). Poststudy chemotherapy was received by 66.1% versus 71.7% of patients with KRAS wild-type tumors in the cetuximab plus FOLFIRI compared with FOLFIRI alone group, respectively. Poststudy EGFRtargeted therapy (with or without chemotherapy) was administered to 10.8% versus 30.9% of patients in these groups, respectively.
Clinical Impact of Tumor BRAF Mutation in Patients With KRAS Wild-Type Tumors
BRAF V600E mutations were detected in 60 (6%) of 999 tumor samples evaluable for both BRAF and KRAS. In all but one case, these mutations were identified in tumors which were wild-type for KRAS. The impact of BRAF tumor mutation status in relation to the efficacy of cetuximab plus FOLFIRI was examined in the population of patients with KRAS wild-type disease (n ϭ 625). Patients whose tumors were wild-type for both genes who received cetuximab plus FOLFIRI had a significantly reduced risk of disease progression (HR, 0.637; P ϭ .0013) and significantly increased odds of response (odds ratio, 2.175; P Ͻ .001) compared with those who received FOLFIRI alone (Table 3 ). The overall survival benefit in this group was no longer significant (HR, 0.830; P ϭ .0547; Appendix Fig A1, Table A1 ). In patients whose tumors were KRAS wild-type/BRAF mutant, improvements in PFS (median 8.0 v 5.6 months; HR, 0.934; P ϭ .87) and overall survival (median, 14.1 v 10.3 months; HR, 0.908; P ϭ .74) associated with the addition of cetuximab to FOLFIRI did not reach statistical significance (Table 3 ; Appendix Fig A1) . There was no evidence of an independent treatment by tumor BRAF mutation status interaction. Thus, with the current data set, BRAF mutation status cannot be shown to be predictive of treatment effects of cetuximab plus FOLFIRI. BRAF V600E mutation indicated poor prognosis in patients with KRAS wild-type disease in both treatment groups, with those whose tumors carried BRAF mutations having a worse outcome for all efficacy end points compared with those whose tumors were wild-type (Table 3 ; Fig 2C) .
Safety
The most common grade 3/4 AE in the safety population was neutropenia, which occurred in 28.2% of patients receiving cetuximab plus FOLFIRI and 24.9% of those receiving FOLFIRI alone. As expected, the incidences of skin reactions, diarrhea, and infusion-related reactions were somewhat higher in patients in the cetuximab plus FOLFIRI compared with the FOLFIRI alone group. Toxicity profiles according to treatment arm were comparable for the safety and KRAS 
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As assessed by an independent review committee for the primary confirmatory analysis.
1 †Best overall response rate ϭ (complete response ϩ partial response).
populations and for the subpopulations with KRAS wild-type and mutant tumors (Table 4) .
DISCUSSION
With knowledge of the predictive value of tumor KRAS mutation status in relation to the efficacy of cetuximab [4] [5] [6] [7] and the EGFR immunoglobulin G2 monoclonal antibody panitumumab 17 in pretreated patients, the CRYSTAL study data were reanalyzed according to tumor KRAS status. Clinical material from which tumor DNA could be successfully analyzed was initially available for a subset of 45% of patients. Subsequently, by using improved ascertainment approaches, the number of patients for whom tumor KRAS mutation status could be determined was approximately doubled to 89%. It was anticipated that the increase in the number of patients evaluable for the status of this biomarker and the increased follow-up time for survival would allow more accurate assessment of the impact of tumor KRAS mutation status. We report an updated analysis in the larger cohort, as well as novel data on the impact of tumor BRAF mutations on clinical outcome.
The updated analysis indicated that the addition of cetuximab to FOLFIRI significantly improved overall survival in the first-line treatment of patients with mCRC compared with FOLFIRI alone. A significant interaction between tumor KRAS mutation status and treatment effect was demonstrated for all key efficacy end points, and analyses within the individual treatment arms indicated that the clinical benefit conferred by cetuximab was limited to patients with KRAS wild-type disease. The median survival time of 23.5 months for patients with KRAS wild-type mCRC who received cetuximab plus FOLFIRI is among the longest reported for a randomized phase III study in this setting. It should also be noted that the HRs for overall survival favoring the cetuximab plus FOLFIRI group were similar in both the initial and updated data sets for patients with KRAS wild-type tumors (0.84 and 0.796, respectively). A further factor that should be considered is that although the overall survival results were most likely impacted by an unbalanced administration of EGFR-targeting agents as poststudy therapy, a clinically relevant survival benefit was nevertheless demonstrated. As to which of the currently approved targeted agents is the most effective when used in combination with FOLFIRI as firstline treatment for patients with mCRC, or particular subgroups of such patients, the difficulties inherent in cross-study comparisons preclude the formulation of a definitive answer.
The CRYSTAL study results are consistent with the updated data from the randomized phase II Oxaliplatin and Cetuximab in FirstLine Treatment of Metastatic Colorectal Cancer (OPUS) study, which confirmed KRAS tumor mutation status as an effective biomarker for the efficacy of cetuximab plus oxaliplatin, leucovorin, and infusional fluorouracil in the first-line treatment of patients with KRAS wild-type mCRC. 18 These data are therefore entirely consistent with the revised guidance from regulatory and advisory authorities concerning the administration of cetuximab only to patients with KRAS wild-type mCRC.
19-22 They confirm KRAS tumor mutation status as a powerful predictive biomarker in this setting in relation to the clinical efficacy of cetuximab combined with standard first-line chemotherapy. It is anticipated that further investigations will yield additional clinical and molecular markers enabling the accurate prediction of which patients with KRAS wild-type mCRC are most likely to derive a clinical benefit from cetuximab treatment. It was in this context that tumor BRAF mutation status was examined in this study.
Patients in both arms with KRAS wild-type disease whose tumors carried BRAF V600E mutations were found to have worse outcomes for all efficacy end points compared with those with tumors wild-type at this codon, thereby confirming this mutation as a strong indicator of poor prognosis in patients receiving chemotherapy alone. These 
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In addition to the 1,198 patients of the intention-to-treat population, the CRYSTAL study safety population included four other patients (one included in the KRAS wild-type group) who were treated but did not undergo random assignment.
†No grade 4 reactions in relation to any MedDRA preferred term included in skin reactions composite categories.
data are consistent with the biomarker analysis of patient tissues from the randomized Fluorouracil, Oxaliplatin, and Irinotecan: Use and Sequencing (FOCUS) and CAIRO2 studies, which demonstrated that tumor BRAF mutation was a negative prognostic marker for overall survival in patients with mCRC. 12,23 Indeed, this strong prognostic effect may explain at least in part why previous single-arm retrospective mCRC analyses have been interpreted as perhaps indicating that EGFR-targeted therapy is ineffective in patients with BRAF mutant tumors. 11, 24, 25 In this study, although there was a marginal trend toward improved PFS and overall survival in patients with KRAS wild-type/BRAF mutant tumors receiving cetuximab plus FOLFIRI compared with FOLFIRI alone, whether this biomarker is a negative predictor in relation to cetuximab benefit could not be definitively addressed given the relatively small number of patients with BRAF mutations. Other candidate biomarkers which may have predictive utility in this setting include high level expression in tumors of the EGFR ligands amphiregulin and epiregulin, [26] [27] [28] and tumor mutation status of the PIK3CA 13, 29, 30 gene. In summary, this study has demonstrated unequivocally that the addition of cetuximab to FOLFIRI as first-line therapy for mCRC improves overall survival compared with FOLFIRI alone in patients whose tumors are wild-type for KRAS. BRAF tumor mutation status is a strong indicator of poor prognosis and should be considered as a stratification factor for future mCRC studies. 
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